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ABSTRACT  
Objective: The present research work was designed to formulate and optimize doxorubicin HCl proniosomes by design of experiment (DoE). 
Methods: A 4-factor, 3-level Box-Behnken design was used to explain multiple linear regression analysis and contour 3D plot responses. The 
independent variables selected were tween 20, cholesterol, hydration volume and sonication time; dependent variables percentage entrapment 
efficiency (PEE), mean vesicle size (MVS). Based on the Box-Behnken design 29 trial runs were studied and optimized for PEE and MVS. Further 
"Model F-Value" was calculated to confirm the omission of insignificant terms from the full-model equation to derive a multiple linear regression 
analysis to predict the PEE and MVS of niosomes derived from proniosomes. 3D plots were constructed to show the influence of independent 
variables on dependent variables.  
Results: PEE of doxorubicin HCl proniosomes was found to be in the range of 40.21-87.5%. The polynomial equation for PEE exhibited a good 
correlation coefficient (0.5524) and the "Model F-Value" of 7.41 implies the model is significant. P-values less than 0.0500 indicate model terms are 
significant. The MVS of doxorubicin HCl proniosomes was found to be in the range of 325.2 nm to 420.25 nm. The mathematical model generated for 
MVS (R2) was found to be significant with model F-value of 54.22. There is only a 0.01% chance that a "Model F-Value" this large could occur due to 
noise (P<0.0500) and R2
Conclusion: The DoE of Box-Behnken design demonstrated the role of the derived equation, 3D plot in predicting the values of dependent variables 
for the preparation and optimization of doxorubicin HCl proniosomes. The results suggest that doxorubicin HCl proniosomes can act as a promising 
carrier. 
 value of 0.9004. 
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In new and existing development of formulations pharmacist 
generally experiments by a series of logical steps, carefully 
controlling the different variables and changing one at a time until 
satisfactory results are obtained. This is how the optimization is 
done in the pharmaceutical company. Optimization is defined as 
follows: “Choosing the best element from some set of available 
alternatives”. It is the process of finding the best way of using the 
existing resources while taking in to the account of all the factors 
that influence decisions in any experiment. The objective of 
designing quality formulation is achieved by various Optimization 
techniques like DoE (Design of Experiment) [1]. 
DoE is a mathematical tool, for systematically planning and 
conducting scientific studies that change experimental variables 
together in order to determine their effect on a given response [2-7]. 
It makes controlled changes to input variables in order to gain 
maximum amounts of information on cause and effect relationships 
with a minimum sample size for optimizing the formulation. There 
are mainly four steps associated with DoE viz., design of the 
experiment (By using various models); a collection of the data; 
statistical analysis of the data and conclusions reached and 
recommendations made as a result of the experiment. In 
optimization method various types of the model used from 
preliminary screening of factors to select their level and for finally 
study of their effect so it’s depend upon the formulator to choose a 
suitable model for study and help in minimizing the experimenting 
time and expenses.  
An experimental design is a statistical design that advises a set of 
combination of variables. The number and layout of these design 
points within the experimental region, depends on the number of 
effects that must be estimated. Depending on the number of factors, 
their levels, possible interactions and order of the model, various 
experimental designs are chosen. Each experiment can be 
represented as a point within the experimental domain, the point 
being defined by its co-ordinate (the value given to the variables) in 
the space [8-10]. 
Doxorubicin HCl is an antineoplastic agent occurred as orange-red, 
crystalline, hygroscopic powder soluble in water and slightly soluble 
in methanol. The mechanism of action of doxorubicin HCl is related to 
its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture 
studies have demonstrated rapid cell penetration and perinucleolar 
chromatin binding, rapid inhibition of mitotic activity and nucleic acid 
synthesis, mutagenesis and chromosomal aberrations. The oral 
bioavailability of about 0.5%-1%, excretion is about 4-5% of the 
administered dose in five days, the half-life is observed phase of 12 
min, second phase 3.3h and prolonged third phase about 29.6h [11]. 
In the present study, the conventional slurry method was used for 
the preparation of doxorubicin HCl proniosomes and optimized. 
MATERIALS AND METHODS  
To 
check the influence of formulation variables on responses 
optimization technique was studied. A Box-Behnken design was 
created using Design Expert 11 (Trial Version 11, Stat-Ease Inc., 
Minneapolis, MN) to interpret the results.  
Materials 
Doxorubicin HCl was obtained as a gift sample from Shilpa antibiotic 
Pvt Ltd, Raichur. Maltodextrin was procured from Himedia, Hosur, 
cholesterol, tween 20 and DCP (Dicetyl phosphate) were purchased 
from Loba chem Pvt Ltd, Mumbai. All the other ingredients and 
reagents used were of analytical grade. 
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Design of experiments (DoE) 
Initially, primary experiments (one factor at a time approach) 
were performed to determine the main factors and the 
appropriate ranges in which the optima lie. Among all the non-
ionic surfactants tween 20 was selected based on results of the 
preliminary experiments [12].  
Further, the effect of four factors (concentrations of surfactant, 
cholesterol, hydration volume and sonication time), three levels on 
the (PEE) and MVS were optimized. The independent factors and the 
dependent variables used in the design are listed in table 1. 
  
Table 1: List of dependent and independent variables in box-behnken design 
Independent variables Levels 
Variables names Low Medium High 
1 Conc. of tween 20 40% 60% 90% 
2 Conc. of cholesterol 10% 30% 
3 
60% 
Sonication time 5 min 10 min 15 min 
4 Hydration volume 5 ml 10 ml 15 ml 
 Dependent variables Goals 
R1 Percentage entrapment efficiency (PEE %) Maximize 
R2 Mean vesicle size (MVS nm) Minimize 
 
Preparation of proniosomes 
The proniosomes were prepared by the slurry method.250 µmol stock 
solution of tween 20, cholesterol and sonication time was prepared in 
chloroform: methanol (2:1). The accurately measured volumes of 
tween 20 and cholesterol stock solutions and doxorubicin HCl (50 mg) 
dissolved in chloroform: methanol (2:1) solutions were added into a 
250 ml round bottom flask containing previously 900 mg of 
maltodextrin powder used as carrier. Additional chloroform: methanol 
(2:1) solution added form slurry. Further the flask was attached to a 
rotary flash evaporator rotated at 60 to 70 rpm. The solvent is allowed 
to evaporate at the temperature of 45±2 °C in a reduced pressure of 
600 mm/Hg until the mass in the flask become a dry, free-flowing 
product. The obtained proniosome powder was further dried 
overnight in desiccators under vacuum at room temperature. The 
obtained dry proniosome powders were stored in airtight amber 
colored vials and kept in a refrigerator for further evaluation [13]. 
Characterization of proniosomes 
The proniosomes were used for the preparation of niosomes and 
characterization of the surface characteristics by optical microscopy. 
Proniosomes were transformed to niosomes by hydrating with 
phosphate buffer saline (PBS) pH 7.4 at 80 °C using vortex mixer for 
2 min. The niosomes were sonicated twice for specified time and 
were characterized for morphology, PEE and MVS. 
Particle size and size distribution analysis 
For all the batches of doxorubicin HCl proniosomes particle size 
analysis was carried out using a compound microscope (optical 
microscope). The freshly prepared hydrated proniosomes were 
dispersed in double distilled water (DDW) and was used to 
characterize the particle size. Size measurements were done in 
triplicate for each sample. Polydispersity Index (PDI) was also 
determined as a measure of homogenecity.  
Entrapment efficiency 
Niosome entrapped doxorubicin HCl was estimated by the dialysis 
method. The calculated amount of prepared niosomes was placed in 
the dialysis bag (presoaked for 24 h). Free doxorubicin HCl was 
dialyzed for 30 min each time in 100 ml of phosphate buffer pH 7.4. 
The dialysis of free doxorubicin HCl always completed after12-15 
changes, when no doxorubicin HCl was detectable in the recipient 
solution. The dialyzed doxorubicin HCl was determined by finding 
out the concentration of bulk of solution by UV spectrophotometer 
at 235 nm. The samples from the bulk of solution diluted 
appropriately before going for absorbance measurement. The free 
doxorubicin HCl in the bulk of solution gives us the total amount of 
unentrapped drug. The percentage entrapment efficiency is 
calculated by using the following formula [14]. 
 
In vitro drug release and release kinetics 
The release of doxorubicin HCl from niosomes derived from 
proniosome was determined using membrane diffusion technique. 
The niosome suspension prepared from proniosomes equivalent to 50 
mg of doxorubicin HCl was taken in a glass tube having a diameter 2.5 
cm with an effective length of 8 cm that was previously covered with 
soaked osmosis cellulose membrane, which acts as a donor 
compartment. The glass tube was placed in a beaker containing 200 ml 
of phosphate buffer pH 7.4, which acts as a receptor compartment. The 
whole assembly was fixed in such a way that the lower end of the tube 
containing suspension was just touched (1-2 mm deep) the surface of 
diffusion medium. The temperature of receptor medium maintained at 
37±1 °C and the medium was agitated at 100 rpm speed using 
magnetic stirrer. Aliquots of 5 ml sample were withdrawn periodically 
and after each withdrawal, same volume of medium was replaced to 
maintain sink condition. The collected samples were analyzed at 235 
nm for doxorubicin HCl using phosphate buffer pH 7.4 as blank. The 
diffusion studies were carried out in triplicate and the data were 
interpreted, model fitted by using dissolution software PCP-DISSO V.3. 
RESULTS AND DISCUSSION  
Preparation of doxorubicin HCl proniosomes 
In this study, the doxorubicin HCl proniosomes were formulated, 
optimized and evaluated for its efficacy in drug delivery to overcome 
the major issues associated with its oral delivery. Primary 
experiments conducted using different non-toxic and biocompatible 
non-ionic surfactants like span together with cholesterol and DCP. 
The phase transition temperature plays a crucial role in the 
doxorubicin HCl proniosomes formulation. Based on the results of 
preliminary experiments, tween 20 was selected as a suitable 
surfactant for the preparation of doxorubicin HCl proniosomes.  
Optimization of formulation variables 
Through primary experiments the four factors viz., concentration of 
tween 20, the concentration of cholesterol, hydration volume and 
sonication time were identified as the most significant variables 
influence the PEE (R1) and MVS (R2).  
The formulations were further optimized by considering the parameters 
like maximum entrapment efficiency and smaller particle size. Twenty-
nine runs performed for the response surface methodology based on the 
Box–Behnken design. Based on the DoE, the factor combinations yielded 
different responses as presented in table 2. These results clearly specify 
that the dependent variables are strongly dependent on the selected 
independent variables as they show a wide variation among all the 29 
batches to obtain analysis of variance (ANOVA), regression coefficients 
and regression equation. Mathematical relationships were generated 
using multiple linear regression analysis for the mentioned variables 
as shown in table 3. These equations represent the quantitative effect 
of concentration of tween 20, concentration of cholesterol, hydration 
volume and sonication time and their interaction on PEE (R1) and 
MVS (R2). 
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Table 2: Box-behnken DoE and observed responses 
Run Factor 1 Factor 2 Factor 3 Factor4 Response 1 Response 2 
Surfactant Cholesterol Hydration volume Sonication time PEE MVS 
 % % ml min % nm 
1 -1 1 1 1 40.21 400.1 
2 -1 -1 -1 -1 43.21 325.2 
3 0 0 0 0 45.21 351.21 
4 1 1 1 1 61.1 402.12 
5 -1 -1 1 1 45.25 329.21 
6 1 -1 1 -1 63.25 332.21 
7 1 1 -1 -1 65.75 406.21 
8 0 0 0 0 47.52 355.4 
9 -1 -1 1 -1 47.25 335.75 
10 1 0 0 0 68.45 360.12 
11 0 0 0 0 48.95 362.75 
12 -1 0 0 0 48.75 368.12 
13 1 -1 -1 1 70.12 339.25 
14 1 -1 1 1 72.15 341.21 
15 0 0 0 1 50.21 370.1 
16 -1 1 -1 1 50.75 408.95 
17 0 0 0 -1 52.85 372.12 
18 1 1 -1 1 73.76 410.85 
19 0 0 1 0 54.95 376.12 
20 1 -1 -1 -1 75.95 346.75 
21 0 1 0 0 87.5 412.35 
22 -1 -1 -1 1 52.21 348.21 
23 0 0 0 0 59.35 380.12 
24 0 0 0 0 62.25 385.21 
25 -1 1 1 -1 53.75 415.95 
26 -1 1 -1 -1 55.75 418.85 
27 0 -1 0 0 65.32 351.21 
28 0 0 -1 0 65.85 391.21 
29 1 1 1 -1 79.11 420.25 
Each formulation containing doxorubicin HCl 50 mg 
 
Table 3: Regression equation for the responses-PEE (R1) and MVS (R2) 





The values of the coefficients of 1, 2, 3 and 4 are related to the effect 
of these variables on the responses R1and R2. Coefficients with 
more than one-factor term and those with higher order terms 
represent interaction terms and quadratic relationship respectively. 
A positive sign represents a synergistic effect, while a negative sign 
indicate antagonistic effect. 
PEE of doxorubicin HCl proniosomes was found to be in the range of 
40.21–87.5% as shown in table 2. The polynomial equation for PEE 
exhibited a good correlation coefficient (0.5524) and the model F-
value of 7.41 implies the model is significant. There is only a 0.05% 
chance that a "Model F-Value" this large could occur due to noise. P-
values
  
 less than 0.0500 indicate model terms are significant. The 3D 
response surfaces plots of the response R1are shown in fig. 1 and 2 
to depict the interactive effects of independent variables on 
response R1, one variable was kept constant while the other three 
variables varied in a certain range. 
 
Fig. 1: Response surface plots showing the interactions between concentration of tween 20 and concentration of cholesterol on PEE 
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Fig. 2: Response surface plots showing the interactions between sonication time and hydration volume on PEE 
 
The mean vesicle size of doxorubicin HCl proniosomes was found to 
be in the range of 325.2 nm to 420.25 nm. The mathematical model 
generated for MVS (R2) was found to be significant with Model F-
value of 54.22. There is only a 0.01% chance that a "Model F-Value" 
this large could occur due to noise (P<0.0500) and R2
 
 value of 
0.9004. The model indicated the linear relationship between particle 
size and independent variables. The independent variables 1, 2, 3 
and 4 have linear effects on the particle size. The influence of the 
main and interactive effects of independent variables on the particle 
size was further elucidated using the perturbation and 3D response 
surface plots. The relationship between the dependent and 
independent variables was further elucidated using 3D response 
surface plots fig. 3 shows the interactive effect of 1 and 2 on the 
particle size (R2) at a fixed level of 3 and 4 and fig. 4 shows the 
interactive effect of 3 and 4 on the particle size (R2) at a fixed level 
of 1 and 2. At low levels of 2 (concentration of cholesterol), R2 
increases from 325.2 nm to 451.21 nm. Similarly, at high levels of 2, 
R2 increases from 400.1 nm to 420.25 nm. 
 
Fig. 3: Response surface plot showing the influence of concentration of tween 20 and concentration of cholesterol on particle size 
 
 
Fig. 4: Response surface plot showing the influence of sonication time and hydration volume on particle size 
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Optimization and confirmation of DoE  
A numerical optimization technique using the desirability approach 
was employed to prepare maltodextrin based doxorubicin HCl 
Proniosomes with the desired responses. Constraints like 
minimizing the MVS in addition to maximizing the PEE were set as 
goals to locate the optimum settings of independent variables. The 
optimized levels and predicted values of R1 and R2 are shown in 
table 4. All the four batches of obtained doxorubicin HCl 
proniosomes were subjected to further characterization. 
 
Table 4: Optimized values obtained by the constraints apply on R1 and R2 
Independent 
variables 
Nominal values Predicted values Codes Observed values 
PEE % R1 MVS nm R2 PEE % R1 MVS nm R2 
Conc. of surfactant(1) 60% 90.11 386.43 FD-1 73.76 412.35 
Conc. of cholesterol(2) 30% FD-2 75.95 415.95 
Hydration volume (3) 10 ml FD-3 87.54 376.96 
Sonication time (4) 10 min FD-4 79.11 418.95 
n=3, Drug-50 mg 
 
The mean vesicle size of diluted doxorubicin HCl proniosomes are 
shown in table 4, it ranges from 376.96±1.25 nm to 418.95±1.20 nm 
with unimodal particle size distribution, which favors drug delivery 
of doxorubicin HCl. Since the smaller particle size is advantageous to 
decrease the irritation, cardiac arrest and improve the penetration 
of particles into the tissues thereby decreases toxicity. The PDI in all 
the formulations was low (<0.024), which indicated the 
homogenecity of the preparation. All the maltodextrin-based 
doxorubicin HCl proniosomes formulations were negatively charged, 
which was due to the negative charge present on the DCP (table 5). 
  
Table 5: PEE, PDI and mean vesicle size of optimized formulations 
Codes PEE %±SD PDI MVS(nm)±SD PDI 
FD-1 73.76±0.25 0.117 412.35±0.23 0.025 
FD-2 75.95±0.35 0.113 415.95±0.52 0.024 
FD-3 87.54±0.29 0.098 376.96±0.42 0.027 
FD-4 79.11±0.55 0.109 418.95±0.22 0.024 
n=3(p<0.05) 
 
Doxorubicin HCl proniosomes prepared using the optimum ratio of 
surfactant (tween 20) and cholesterol demonstrated lamellar 
structures under the compound microscope. Hydration of dry 
proniosomes with pH 7.4 phosphate buffer solution leads to swelling 
of bilayers as well as particles due to the interaction of water with 
polar groups of surfactant. The bilayer tends to form spherical 
structure randomly giving rise to multilamellar, multivesicular 
structures. When shaken with aqueous phase, complete hydration 
takes place leading to the formation of niosomes. Observation under 
optical microscope revealed that maltodextrin based doxorubicin 
HCl proniosomes was rapidly converted to niosomes almost 
completely within minutes. 
In vitro drug release and release kinetics 
It is clear that the cumulative release of drug from control (pure 
drug) was faster than from the doxorubicin HCl proniosomes. This 
was due to the fact that doxorubicin HCl was sufficiently hydrophilic 
and it partitions in favour of the proniosomes, which resulted in the 
slower release of doxorubicin HCl proniosomes. 
 
 
Fig. 5: In vitro release of doxorubicin HCl and doxorubicin HCl proniosomes (FD-3) 
 
The in vitro drug release from the pure doxorubicin HCl was found 
to be 94.50±0.16 FD-3 was found to be 40.2±0.24 after 6h and 
53.7±0.54 after 9h. The drug release about 28 to 43% after 6h is 
mainly due to initial bursting of improper niosome and adhered 
drug particles in formulations and at the start of 24h the release was 
found to be steady because stable niosomes retains and the release 
Srikanth et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 7, 90-95 
 
95 
was extended up to 36h with sustained action. The best fit model 
was found to be Hix. Crow for pure doxorubicin, best fit model was 
found to be Ist 
CONCLUSION  
order for FD-3. The korsemayer peppas exponential 
n<0.84 indicate the release mechanism was non fickanian 
(anomalous transport) i.e. drug released by erosion followed by 
diffusion mechanism. 
The present study conclusively demonstrates the use of Box-
Behnken design in formulation and optimization of maltodextrin 
based doxorubicin HCl niosome derived from proniosomes 
formulations to avoid its systemic toxicity. This study indicated that 
niosome can be optimized to achieve desired properties using tween 
20 concentrations, cholesterol concentration, sonication time, and 
hydration volume. The optimized niosome formulation 
demonstrated enhanced PEE and optimum MVS.  
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